An Open-label Extension (OLE 2) Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert in Subjects With Open-angle Glaucoma or Ocular Hypertension Who Have Completed Study FSV5-004
Phase of Trial: Phase I/II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Bimatoprost (Primary)
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Adverse reactions
- Sponsors ForSight VISION5
- 08 Nov 2017 According to an Allergan media release, pooled results from this and another open-label extension trial will be presented at the annual American Academy of Ophthalmology (AAO) meeting.
- 08 Aug 2016 Status changed from recruiting to completed.
- 04 Sep 2015 New trial record